SCHEMBL23013103

SCHEMBL23013103

CCOC(=O)c1c(-c2ccc(N3CCCC3)cc2F)nn2cccnc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 1/20 0.40
JAK3 P52333 1/20 0.40
DGAT1 O75907 3/20 0.38
SOAT1 P35610 2/20 0.38
METAP1 P53582 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
CDC7 O00311 1/20 0.37
SLC34A1 Q06495 1/20 0.36
KCNQ3 O43525 1/20 0.36
KCNQ2 O43526 1/20 0.36
JMJD6 Q6NYC1 2/20 0.36
TP53 P04637 1/20 0.36
MAPT P10636 1/20 0.36
TGFBR1 P36897 1/20 0.36
KDM4E B2RXH2 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
PDE2A O00408 1/20 0.35
SIRT2 Q8IXJ6 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29692297 1.00 JAK2 (0.40) JAK2JAK3DGAT1SOAT1METAP1
SCHEMBL29939370 0.86 SLC34A1 (0.45) JAK2JAK3CDC7SLC34A1KCNQ3
SCHEMBL27230012 0.85 ALOX5 (0.41) SLC34A1KCNQ3KCNQ2JMJD6MAPT
SCHEMBL23023570 0.85 L3MBTL1 (0.41) JAK2JAK3KDM4E
SCHEMBL29939653 0.85 MAPT (0.40) JAK2JAK3SLC34A1KCNQ3KCNQ2
SCHEMBL30029164 0.84 PRKCZ (0.49) JAK2JAK3SLC34A1TP53MAPT
SCHEMBL23023716 0.83 KDM4E (0.44) JAK2JAK3DGAT1SOAT1CDC7
SCHEMBL29939563 0.83 JAK2 (0.47) JAK2JAK3DGAT1SOAT1MAPT
SCHEMBL27230050 0.83 KDM4E (0.38) JAK2JAK3SLC34A1TGFBR1KDM4E
SCHEMBL30988108 0.82 KCNQ3 (0.39) JAK2JAK3SLC34A1KCNQ3KCNQ2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12227507-B2 Pharmaceutical compounds PFIZER INC. (US) 2025-02-18 US disclosed
US-20220324873-A1 PHARMACEUTICAL COMPOUNDS PFIZER INC. 2022-10-13 US disclosed
US-20220306639-A1 PHARMACEUTICAL COMPOUNDS PFIZER INC. 2022-09-29 US disclosed
EP-4017856-A1 PHARMACEUTICAL COMPOUNDS Reviral Limited (GB) 2022-06-29 EP disclosed
WO-2021032992-A1 PHARMACEUTICAL COMPOUNDS ReViral Limited (GB) 2021-02-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12227507-B2 Pharmaceutical compounds CHRNA6, GABRA6, CHRNA7 JAK2 1583/4885JAK3 1631/4885DGAT1 4476/4885
US-20220306639-A1 PHARMACEUTICAL COMPOUNDS CHRNA6, GABRA6, CHRNA7 JAK2 1583/4885JAK3 1631/4885DGAT1 4476/4885
US-20220324873-A1 PHARMACEUTICAL COMPOUNDS GABRA6, CNR1, CHRNA6 JAK2 1458/4885JAK3 1544/4885DGAT1 4382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.